PRINCETON, N.J. — Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.
Sandoz, the generics arm of Swiss drug maker Novartis, announced the launch of authorized generic diclofenac gel in the 3% strength. The drug is a version of PharmaDerm's Solaraze.
The drug had sales of $92 million in 2012, according to IMS Health. Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a contract between the branded drug's manufacturer and a third-party company.
Actinic keratosis, or AK, is a precancerous condition affecting 58 million Americans that causes thick, scaly or crusty patches of skin.